Medical Enzymes AG - Product Pipeline Review - Q4 2010

Summary

Global Market Direct’s pharmaceuticals report, “Medical Enzymes AG - Product Pipeline Review - Q4 2010” provides data on the company’s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects. It also gives a complete picture of the company’s future therapy areas of focus.

This report is built using data and information sourced from Global Markets Direct’s proprietary databases, primary and secondary research using Company’s corporate website, SEC filings, investor presentations and featured press releases, both from company and industry-specific third party sources, put together with in-house analysis, by Global Markets Direct’s team of industry experts.

Scope

- Medical Enzymes AG - company overview including business description, key employees, and other facts.
- Review of current pipeline of Medical Enzymes AG human therapeutic division.
- Overview of pipeline therapeutics across various therapy areas.
- Coverage of current pipeline molecules in various stages of drug development, including the combination treatment modalities, for the pharmaceutical markets across the globe.
- Product profiles for late stage and clinical stage products of Medical Enzymes AG with complete description of the product’s developmental history, mechanism of action, clinical trials, major milestones and others.
- Recent updates of the Medical Enzymes AG’s pipeline in the last quarter.
- Key discontinued and dormant projects.
- Latest news and deals relating to the products.

Reasons to buy

- Evaluate Medical Enzymes AG’s strategic position with total access to a detailed intelligence on its product pipeline.
- Assess the growth potential of Medical Enzymes AG in its therapy areas of focus.
- Identify new drug targets and therapeutic classes in the Medical Enzymes AG’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas.
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps.
- Exploit collaboration and partnership opportunities with Medical Enzymes AG.
- Avoid Intellectual Property Rights related issues.
- Explore the dormant and discontinued projects of Medical Enzymes AG and identify potential opportunities in those areas.
- Do deals with an understanding of the mergers and partnerships that have shaped the sector.

Contents

1 TABLE OF CONTENTS

1.1 List of Tables
1.2 list of Figures

2 INTRODUCTION
3 MEDICAL ENZYMES AG SNAPSHOT

3.1 Business Description

4 MEDICAL ENZYMES AG- RESEARCH AND DEVELOPMENT OVERVIEW

4.1 Key Therapeutic Areas

5 MEDICAL ENZYMES AG- PIPELINE REVIEW

5.1 Pipeline Products by Stage of Development
5.2 Pipeline Products-Monotherapy
5.3 Pipeline Products-Combination Treatment Modalities

6 MEDICAL ENZYMES AG PIPELINE PRODUCTS GLANCE

6.1 Medical Enzymes AG Phase II Pipeline
6.2 Medical Enzymes AG Phase I Pipeline
6.3 Medical Enzymes AG Pre-Clinical Pipeline

7 MEDICAL ENZYMES AG - DRUG PROFILES

7.1 Product
  7.1.1 Product Description
  7.1.2 Mechanism of Action
  7.1.3 R&D Progress

8 MEDICAL ENZYMES AG PIPELINE ANALYSIS

8.1 Medical Enzymes AG Pipeline Products by Therapeutic Class
8.2 Medical Enzymes AG Pipeline Products by Target
8.3 Medical Enzymes AG Pipeline by Route of Administration
8.4 Medical Enzymes AG Pipeline Products by Molecule Type

9 MEDICAL ENZYMES AG- RECENT PIPELINE UPDATES
10 MEDICAL ENZYMES AG- DORMANT PIPELINE PROJECTS

10.1 Feature on Dormant Projects

11 MEDICAL ENZYMES AG- DISCONTINUED PIPELINE PRODUCTS

11.1 Discontinued Pipeline Product Profiles
  11.1.1 Product

12 MEDICAL ENZYMES AG – FEATURED NEWS
13 MEDICAL ENZYMES AG STATEMENT

13.1 Medical Enzymes AG - Locations and Subsidiaries

14 APPENDIX

14.1 Global Markets Direct Research Methodology
14.2 Coverage
14.3 Secondary Research
14.4 Primary Research
14.5 Models
14.6 Expert Panels
14.7 Contact Us
14.8 Disclaimer

LIST OF TABLES

Table 1: Medical Enzymes AG - Key Information
Table 2: Medical Enzymes AG - Key Facts
Table 3: Medical Enzymes AG - Key Therapeutic Areas
Table 4: Medical Enzymes AG - Pipeline by Stage of Development,
Table 5: Medical Enzymes AG - Monotherapy Products in Pipeline,
Table 6: Medical Enzymes AG - Combination Treatment Modalities in Pipeline,
Table 7: Medical Enzymes AG - Phase II Pipeline,
Table 8: Medical Enzymes AG - Phase I Pipeline,
Table 9: Medical Enzymes AG - Pre-Clinical Pipeline,
Table 10: Medical Enzymes AG - Pipeline By Therapeutic Class
Table 11: Medical Enzymes AG - Pipeline By Target
Table 12: Medical Enzymes AG - Pipeline By Route of Administration
Table 13: Medical Enzymes AG - Pipeline By Molecule Type
Table 14: Medical Enzymes AG - recent Pipeline Updates
Table 15: Medical Enzymes AG - Dormant Pipeline Projects

LIST OF FIGURES

Figure 1: Medical Enzymes AG - Research and Development Overview
Figure 2: Medical Enzymes AG - Pipeline by Stage of Development,
Figure 3: Medical Enzymes AG - Monotherapy Products in Pipeline,
Figure 4: Medical Enzymes AG - Combination Treatment Modalities in Pipeline,
Figure 5: Medical Enzymes AG - Pipeline By Therapeutic Class and Stage of Development
Figure 6: Medical Enzymes AG - Pipeline By Therapeutic Class
Figure 7: Medical Enzymes AG - Pipeline By Target and Stage of Development
Figure 8: Medical Enzymes AG - Pipeline By Target
Figure 9: Medical Enzymes AG - Pipeline By Route of Administration and Stage of Development
Figure 10: Medical Enzymes AG - Pipeline By Route of Administration
Figure 11: Medical Enzymes AG - Pipeline By Molecule Type and Stage of Development
Figure 12: Medical Enzymes AG - Pipeline By Molecule Type

COMPANIES MENTIONED

Medical Enzymes AG Skip to top